# EDIT — replay s2 — bf16

## Metadata

ticker: EDIT
arm: bf16
sample: 2
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/EDIT_local-model.md
context_sha256: 35fd11f194201b563e370554975b823c3e44bf58552a16df1b8ce296004ac7c4
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:21:57Z
financial_health_prompt_sha256: 6e28dd79a4b0a230673259741e3f59019f7eed8327bd6bfa00ee7fe0c57b72ae
financial_health_seed: 20152
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 52
risk_factors_prompt_sha256: 8dbe13748e4cb686acbaf3ffd63e2a8667242e81c33546957fbfc75c59880f21
risk_factors_seed: 20153
risk_factors_response_model: financial-lora
risk_factors_finish_reason: length
risk_factors_completion_tokens: 512

## Stock data

{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.69,
  "currency": "USD",
  "market_cap": 413130304.0,
  "forward_pe": -3.5717604,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin": -1.57322,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health

Editas Medicine, Inc., trades under the ticker EDIT. It carries a current stock price of $2.69 per share in the healthcare sector. The company reports net income of -$7.4 billion over the past year.

<!-- replay-section: Risk Factors -->
### Risk Factors Disclosed

The company faces several significant risks that could have material adverse effects on its business, financial condition, results of operations, and prospects. These risks include but are not limited to:

#### Financial Position and Capital Needs
- The company has incurred substantial accumulated losses of $1.6 billion as of December 31, 2025. It also expects to incur losses for the foreseeable future and may never achieve profitability.
- The company's ability to raise additional capital, if needed, is subject to market conditions and general economic conditions, which may limit the amount and timing of any such capital resources available to it.
- The company may need to seek additional financing through public or private equity offerings, debt financings, or other means. There can be no assurance that the company will be able to secure additional financing when needed or on terms acceptable to the company.
- If the company is unable to obtain sufficient additional capital resources on favorable terms, the company may be forced to delay, scale back, or discontinue some or all of its research and development activities, product candidate development efforts, and/or commercialization efforts, which would materially harm its business, financial condition, results of operations, and prospects.

#### Development and Commercialization Challenges
- The company is currently only in preclinical testing stages for its most advanced research programs. This stage involves extensive laboratory work aimed at understanding the basic mechanisms underlying the disease or disorder under investigation. While this stage provides valuable insights into the nature of the disease or disorder and the potential therapeutic targets, it does not provide sufficient information to support the initiation of human clinical trials or the submission of an Investigational New Drug application to the FDA or equivalent foreign regulatory authority.
- In addition to the challenges associated with the early-stage development and preclinical testing phases of drug discovery and development, there are numerous other challenges that must be overcome before a new drug candidate can be considered ready for human clinical trials. These challenges include, but are not limited to: the need to identify and validate appropriate animal models of the disease or disorder under investigation; the need to conduct extensive toxicology studies and other preclinical safety evaluations to ensure that the drug candidate is safe for use in humans; the need to conduct extensive pharmacokinetic and pharmacodynamic studies to determine the optimal dosing regimen and other relevant parameters for the drug candidate; the need to conduct extensive clinical efficacy and safety studies in humans to evaluate the effectiveness and safety of the drug candidate for treating the disease or disorder under investigation; and the need to conduct extensive post-mark
